再鼎医药今日盘中大涨5.94%，引起了市场的广泛关注。
消息面上，再鼎医药宣布与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向DLL3的抗体药物偶联物zoci联合安进的塔拉妥单抗，用于治疗广泛期小细胞肺癌患者。
根据合作协议，安进将申办一项全球1b期研究，评估该联合疗法的安全性和有效性。再鼎医药将保留zoci的完整所有权，并向安进提供临床研究用药。此次合作被视为公司研发管线的重要进展，增强了市场对其未来增长潜力的信心。
再鼎医药今日盘中大涨5.94%，引起了市场的广泛关注。
消息面上，再鼎医药宣布与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向DLL3的抗体药物偶联物zoci联合安进的塔拉妥单抗，用于治疗广泛期小细胞肺癌患者。
根据合作协议，安进将申办一项全球1b期研究，评估该联合疗法的安全性和有效性。再鼎医药将保留zoci的完整所有权，并向安进提供临床研究用药。此次合作被视为公司研发管线的重要进展，增强了市场对其未来增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.